Spark Plug Pipe

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced a presentation at the 27 European Academy of Dermatology & Venereology Congress (EADV), to be held September 12-16, 2018 in Paris.

Details for the presentation are as follows:

Oral Presentation:Title:       "Clinically Meaningful Reduction of Itch and Improvement in Multiple Quality of Life Measures in Hemodialysis Patients with Moderate-to-Severe Pruritus Following Treatment with Difelikefalin"Date / Time: Thursday, September 13, 2018, 15:00 - 16:30 CETPresenter:   Frederique Menzaghi, Ph.D., Senior Vice President, Research & Development, Cara Therapeutics

For information about EADV, visit https://eadvparis2018.org.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class kappa opioid receptor agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In Phase 2 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients suffering from moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). KORSUVA is currently being investigated in global Phase 3 trials in hemodialysis patients with CKD-aP. Additionally, in a recently completed Phase 2/3 trial in post-operative patients, I.V. CR845/difelikefalin has demonstrated reduction in moderate-to-severe pain, while also reducing the incidence and intensity of nausea and vomiting throughout the post-operative period.

The FDA has conditionally accepted KORSUVA(TM) as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product, and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:

Michael Schaffzin

Stern Investor Relations

212-362-1200

michael@sternir.com

MEDIA CONTACT:

Annie Starr

6 Degrees

973-415-8838

astarr@6degreespr.com

https://resource.globenewswire.com/media/9792299c-7ce7-476e-93da-2260932611ba/small/cara-therapeutics-logo.jpg

<img src=”http://www.globenewswire.com/newsroom/ti?ndecode=MTUwIzczNzMxNzc=” alt=”” width=”1″ height=”1″/>

Stock Symbols